Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases

Patients with inflammatory rheumatic diseases (IRD) are at increased risk for worse COVID-19 outcomes. Identifying whether mRNA vaccines differ in immunogenicity and examining the effects of immunomodulatory treatments may support COVID-19 vaccination strategies. We aimed to conduct a long-term, mod...

Full description

Bibliographic Details
Main Authors: Catherine E. Raptis, Christoph T. Berger, Adrian Ciurea, Diego O. Andrey, Christos Polysopoulos, Pierre Lescuyer, Tanja Maletic, Myriam Riek, Almut Scherer, Isabell von Loga, Judith Safford, Kim Lauper, Burkhard Möller, Nicolas Vuilleumier, Axel Finckh, Andrea Rubbert-Roth
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
vaccination
mRNA-1273
BNT162b2
anti-spike-IgG
waning immunity
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1016927/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1016927/full

Similar Items